Preclinical studies have highlighted how (E,E)-bisantrene silences c-MYC gene expression via G4-DNA binding and stabilization leading to clinically relevant and broad anticancer activity
Rithm Acquisition Corp. (the “Company”) announced today that it had received written notice on January 26, 2026 (the “Notice”) from the New York Stock Exchange (the “NYSE”) that the Company...
Sixty-eight NYSE stocks hit new 52-week highs on Tuesday. Three were SPACs. As stocks become pricier, investor interest has increased. While it's tempting to bet on businesses with a pile of cash to acquire...
Monday U.S. Economic Lookahead Factory orders (Sept.) Featured Earnings Vertex Pharmaceuticals ...